Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 13, 2025

InnoCare’s Mesutoclax obtains breakthrough therapy designation in China

InnoCare’s B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has secured breakthrough therapy designation (BTD) from the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE).

Continue
Clinical studies for Mesutoclax are underway both in China and internationally. Credit: National Cancer Institute on Unsplash.
May 12, 2025

Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

The company has secured approvals to commence Phase I trials of SRSD216, designed to treat hyperlipoproteinemia in individuals with atherosclerotic cardiovascular conditions. Credit: Ali Hajiluyi on Unsplash.
May 9, 2025

MIRA secures board approval to buy SKNY Pharmaceuticals

MIRA develops treatments for neuropsychiatric, neurological, as well as metabolic disorders. Credit: Robina Weermeijer on Unsplash.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Evotec secures $2.5m grant for TB treatment development
  2. FDA grants fast track status to Alterity’s multiple system atrophy treatment
  3. USPTO grants two additional patents to Moleculin’s drug candidate
  4. PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea
  5. CHMP endorses Roche’s breast cancer therapy for administration out of clinical settings

PRESS RELEASES

LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation